113 results match your criteria Parkinson-Plus Syndromes

Predicting Long-Term Outcome of Patients of Early Parkinsonism with Acute Levodopa Challenge Test.

Neurol India 2021 Mar-Apr;69(2):430-434

Department of Neurology, Bangur Institute of Neuroscience and Institute of Post Graduate Medical Education and Research (IPGME&R), Kolkata, West Bengal, India.

Objectives: The aim of this study was to evaluate the sensitivity and specificity of various outcomes of acute levodopa challenge test (ALCT) namely improvement of motor function, development of dyskinesia and intolerance; to predict the diagnosis of idiopathic Parkinson's disease (IPD) or Parkinson-plus syndrome; to predict levodopa responsiveness and levodopa-induced dyskinesia (LID) during long-term therapy.

Methods: ALCT was performed on 89 patients with parkinsonism of <2 years and were followed up for 18 months. Improvement of UPDRSm by ≥30% was considered positive. Read More

View Article and Full-Text PDF

High prevalence of serum anti-NH-terminal of α-enolase antibodies in patients with multiple system atrophy and corticobasal syndrome.

J Neurol 2021 Apr 15. Epub 2021 Apr 15.

Department of Neurology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.

Background: Hashimoto's encephalopathy with serum anti-NH-terminal of α-enolase (NAE) antibodies occasionally displays clinical symptoms such as cerebellar ataxia and parkinsonism. We studied the frequency of anti-NAE antibodies in patients with Parkinson-plus syndrome.

Methods: We examined the positive rates of anti-NAE antibodies in 47 patients with multiple system atrophy (MSA), 29 patients with Parkinson's disease (PD), eight patients with corticobasal syndrome (CBS), and 18 patients with progressive supranuclear palsy (PSP) using conventional immunoblot analysis. Read More

View Article and Full-Text PDF

Identification of GBA mutations among neurodegenerative disease patients from eastern India.

Neurosci Lett 2021 04 9;751:135816. Epub 2021 Mar 9.

S. N. Pradhan Centre for Neurosciences, University of Calcutta, Kolkata, India. Electronic address:

Introduction: GBA mutations have been reported in PD, PDD and DLB - but not associated with cognitive impairment for example in PSP, AD or MSA. However, frequencies of GBA mutations are ethnicity dependent. The present study aims to identify commonly reported GBA mutations (mostly from Asia), among eastern Indian patients with neurodegenerative disorders. Read More

View Article and Full-Text PDF

Hyperhomocysteinemia and Dementia Associated With Severe Cortical Atrophy, but No Amyloid Burden.

J Geriatr Psychiatry Neurol 2021 Jan 19:891988720988910. Epub 2021 Jan 19.

Regionale Brain Aging Center, Department of Medicine (DIMED), University of Padova, Padova, Italy.

We report a case of a 77 years old patient who was admitted to our memory clinic because of progressive gait impairment and amnestic cognitive decline associated with extrapyramidal symptoms and behavioral changes. The clinical picture was consistent with a possible diagnosis of Alzheimer's Disease associated with parkinsonian symptoms or with a Parkinson Plus syndrome. After a complete investigation, she was found to have a high plasma level of homocysteine due to homozygous methylene-tetrahydrofolate reductase (MTHFR) gene C665 T polymorphism, cognitive and motor impairment were associated with a severe cortical atrophy and mild subcortical vascular disease. Read More

View Article and Full-Text PDF
January 2021

Diagnostic performance of loss of nigral hyperintensity on susceptibility-weighted imaging in parkinsonism: an updated meta-analysis.

Eur Radiol 2021 Jan 15. Epub 2021 Jan 15.

Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Olympic-ro 33, Seoul, 05505, Republic of Korea.

Objectives: To evaluate diagnostic performance of loss of nigral hyperintensity on SWI in differentiating idiopathic Parkinson's disease (IPD) or primary parkinsonism (including IPD and Parkinson-plus syndrome) from healthy/disease controls.

Methods: MEDLINE/PubMed and EMBASE databases were searched to identify original articles investigating the diagnostic performance of loss of nigral hyperintensity for differentiating IPD or primary parkinsonism from healthy/disease control, up to April 3, 2020. Pooled sensitivity and specificity were calculated using a bivariate random-effects model. Read More

View Article and Full-Text PDF
January 2021

Comparative Performance of 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT Imaging in Patients With Parkinson's Disease, Parkinson-Plus Syndrome, and Essential Tremor.

Clin Nucl Med 2021 Feb;46(2):95-102

From the Departments of Nuclear Medicine.

Purpose: The aim of this study was to assess the utility of presynaptic dopaminergic imaging using 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT and compare their performance in Parkinson's disease (PD), Parkinson-plus syndrome (PPS), and essential tremor (ET).

Patients And Methods: A total of 103 patients (PD = 48, PPS = 19, and ET = 36) were enrolled prospectively. Hoehn and Yahr (H&Y) staging and MDS-UPDRS (Movement Disorder Society-Sponsored Revision of Unified Parkinson's Disease Rating Scale) were done for PD and PPS cases. Read More

View Article and Full-Text PDF
February 2021

Multimodal analysis of gene expression from postmortem brains and blood identifies synaptic vesicle trafficking genes to be associated with Parkinson's disease.

Brief Bioinform 2020 10 20. Epub 2020 Oct 20.

Head of Department of Neurology, Zhujiang Hospital, Southern Medical University, China.

Objective: We aimed to identify key susceptibility gene targets in multiple datasets generated from postmortem brains and blood of Parkinson's disease (PD) patients and healthy controls (HC).

Methods: We performed a multitiered analysis to integrate the gene expression data using multiple-gene chips from 244 human postmortem tissues. We identified hub node genes in the highly PD-related consensus module by constructing protein-protein interaction (PPI) networks. Read More

View Article and Full-Text PDF
October 2020

Role of variant p.Gly2019Ser in patients with Parkinsonism.

Indian J Med Res 2020 06;151(6):592-597

S.N. Pradhan Centre for Neurosciences, University of Calcutta, Kolkata, India.

Background & Objectives: Parkinsonian disorder, including Parkinson's disease (PD), is an aetiologically complex neurodegenerative disorder. Mutations in leucine-rich repeat kinase 2 (LRRK2) gene have been implicated in an autosomal dominant form of PD with variable penetrance. The identification of a common LRRK2 variant (p. Read More

View Article and Full-Text PDF

Detailed Anatomical Volumetric Study of Deep Nuclei of Brain and Other Structures Between Parkinson's Disease Patients Who Had Deep Brain Stimulation and Control Group.

Malays J Med Sci 2020 May 30;27(3):53-60. Epub 2020 Jun 30.

Department of Radiology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.

Background: Deep brain stimulation (DBS) was pioneered by Neuroscience team of Hospital Universiti Sains Malaysia (HUSM) nearly a decade ago to treat advanced medically refractory idiopathic Parkinson's disease (IPD) patients.

Objectives: Brain volume reduction occurs with age, especially in Parkinson plus syndrome or psychiatric disorders. We searched to define the degree of volume discrepancy in advanced IPD patients and correlate the anatomical volumetric changes to motor symptoms and cognitive function. Read More

View Article and Full-Text PDF

Dysphagia in Parkinsonism: Prevalence, Predictors and Correlation with Severity of Illness Fasting).

J Assoc Physicians India 2020 May;68(5):22-25

Associate Professor, Department of Medicine, LTMMC and GH, Mumbai, Maharashtra.

Introduction: Dysphagia is frequently present in Parkinsonian syndromes and is associated with increased morbidity and mortality. Early identification of swallowing dysfunction is critical to minimize complications like aspiration pneumonia and malnutrition. Published prevalence rates for dysphagia in Parkinsonian syndromes vary widely with a very few studies from India. Read More

View Article and Full-Text PDF

Overview of sleep disturbances and their management in Parkinson plus disorders.

J Neurol Sci 2020 Aug 8;415:116891. Epub 2020 May 8.

Department of Neurology, National Institute of Mental Health & Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka 560029, India. Electronic address:

Sleep disturbance is one of the commonly reported non-motor symptoms in patients with Parkinson's disease (PD) as well as in Parkinson plus disorders such as multiple system atrophy (MSA), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS). Although there is a wealth of literature on sleep disturbances in PD, the same is not robust on the Parkinson plus disorders. This article aims to comprehensively review the sleep disturbances in Parkinson plus disorders. Read More

View Article and Full-Text PDF

DCTN1-related Parkinson-plus disorder (Perry syndrome).

Pract Neurol 2020 Aug 20;20(4):317-319. Epub 2020 May 20.

Department of Neurology, St George's Hospital, London, UK

Dynactin-1 (DCTN1)-related Parkinson-plus disorder (Perry syndrome) is an autosomal dominant neurodegenerative disorder characterised by levodopa-resistant parkinsonism, weight loss, mood change and central hypoventilation. Ventilatory insufficiency is the predominant cause of death. It has been previously described in 87 people from 20 families with a worldwide distribution. Read More

View Article and Full-Text PDF

Locus coeruleus pathology in progressive supranuclear palsy, and its relation to disease severity.

Acta Neuropathol Commun 2020 02 4;8(1):11. Epub 2020 Feb 4.

Cambridge University Centre for Parkinson-plus and Department of Clinical Neurosciences, University of Cambridge, Robinson Way, Cambridge, CB2 0SZ, UK.

The locus coeruleus is the major source of noradrenaline to the brain and contributes to a wide range of physiological and cognitive functions including arousal, attention, autonomic control, and adaptive behaviour. Neurodegeneration and pathological aggregation of tau protein in the locus coeruleus are early features of progressive supranuclear palsy (PSP). This pathology is proposed to contribute to the clinical expression of disease, including the PSP Richardson's syndrome. Read More

View Article and Full-Text PDF
February 2020

Parkinsonism in frontotemporal dementias.

James B Rowe

Int Rev Neurobiol 2019 21;149:249-275. Epub 2019 Nov 21.

Cambridge University Centre for Frontotemporal Dementia and Cambridge University Centre for Parkinson-plus, Cambridge University, Cambridge, United Kingdom.

Frontotemporal dementia is a clinically and pathologically heterogeneous group of neurodegenerative disorders, with progressive impairment of behavior and language. They can be closely related to amyotrophic lateral sclerosis, clinically and through shared genetics and similar pathology. Approximately 40% of people with frontotemporal dementia report a family history of dementia, motor neuron disease or parkinsonism, and half of these familial cases are attributed to mutations in three genes (C9orf72, MAPT and PGRN). Read More

View Article and Full-Text PDF

Urological function and dysfunction in aging: Diagnosis and treatment.

Handb Clin Neurol 2019 ;167:495-509

Center for Health in Aging, Emory University School of Medicine, Atlanta, GA, United States.

Urinary symptoms worsen further the quality of life of persons already burdened by neurologic disease. Urinary symptoms frequently occur in the setting of neurologic diseases such as Parkinson disease and Parkinson-plus syndromes, multiple sclerosis, and stroke. Urinary incontinence is associated with increased caregiver burden and enhances the risk of institutionalization among those living with dementia. Read More

View Article and Full-Text PDF

Recognizing and treating atypical Parkinson disorders.

Handb Clin Neurol 2019 ;167:301-320

Department of Neurology, University of Florida College of Medicine, Gainesville, FL, United States.

Though less common than Parkinson's disease (PD), the atypical Parkinson disorders such as such as dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration are increasingly recognized and important to distinguish from PD. Atypical or "Parkinson-plus" disorders are multisystem disorders and generally progress more rapidly and respond poorly to current therapies compared to PD. Recent advances in our understanding of the pathophysiology of these disorders, however, have generated new interest in the development of novel diagnostics and disease-modifying therapeutics aimed at identifying and treating these disorders. Read More

View Article and Full-Text PDF

Dysphagia in Progressive Supranuclear Palsy.

Dysphagia 2020 08 1;35(4):667-676. Epub 2019 Nov 1.

Department of Neurology, Mayo Clinic, 200 1st Street S.W., Rochester, MN, 55905, USA.

Progressive supranuclear palsy (PSP) is the most common Parkinson-Plus syndrome and is associated with early onset of dysphagia relative to Parkinson Disease. The current study contributes to the growing understanding of swallowing dysfunction in PSP by describing oropharyngeal swallowing characteristics in a large prospective cohort of participants with PSP employing a nationally standardized videofluoroscopy protocol and a disease severity scale developed expressly for PSP. Participants were 51 adults diagnosed with PSP. Read More

View Article and Full-Text PDF

Survival, effect measures, and impact numbers after dementia diagnosis: a matched cohort study.

Clin Epidemiol 2019 16;11:525-542. Epub 2019 Jul 16.

Research Group on Ageing, Disability and Health, Girona Biomedical Research Institute (IDIBGI), Catalonia, Spain.

Background: Knowledge on survival after diagnosis is important for all stakeholders. We aimed to estimate the survival and life expectancy after a dementia diagnosis, and to quantify the impact of dementia subtypes on mortality.

Methods: Retrospective matched cohort study using a linkage between a dementia-specific registry and two primary care electronic medical records databases. Read More

View Article and Full-Text PDF

What Predicts Hospital Admissions in Community-Dwelling People With Parkinsonism?

J Geriatr Psychiatry Neurol 2020 03 13;33(2):103-108. Epub 2019 Aug 13.

Northumbria Healthcare NHS Foundation Trust, North Tyneside General Hospital, Rake Lane, North Shields, Tyne and Wear, United Kingdom.

Objectives: Previous studies have looked at the reasons for hospital admission in people with parkinsonism (PwP), yet few have looked at factors that precipitate admission.

Methods: People with parkinsonism with a diagnosis of idiopathic Parkinson disease of Hoehn and Yahr stage III-V and those with Parkinson plus syndromes were assessed for motor and nonmotor symptoms, quality of life, and functional performance. Logistic regression was used to investigate predictors of hospital admission over the subsequent 2 years. Read More

View Article and Full-Text PDF

Social perceptual function in parkinson's disease: A meta-analysis.

Neurosci Biobehav Rev 2019 09 20;104:255-267. Epub 2019 Jul 20.

School of Psychology, University of Queensland, Brisbane, Australia.

Social perceptual impairment is a common presenting feature of Parkinson's disease (PD) that has the potential to contribute considerably to disease burden. The current study reports a meta-analytic integration of 79 studies which shows that, relative to controls, PD is associated with a moderate emotion recognition deficit (g = -0.57, K = 73), and that this deficit is robust and almost identical across facial and prosodic modalities. Read More

View Article and Full-Text PDF
September 2019

Introduction and classical environmental risk factors for Parkinson.

C Tranchant

Rev Neurol (Paris) 2019 Dec 18;175(10):650-651. Epub 2019 Jun 18.

Service de neurologie, hôpital de Hautepierre, 1, avenue Molière, 67000 Strasbourg, France. Electronic address:

Several environmental toxics are known to induce or to increase occurrence of Parkinson disease while other toxics can provoke basal ganglia necrosis and dopa resistant parkinsonism. After this introduction, the relationship between environment and parkinsonism will be illustrated by 3 short papers: interaction gene-environment, manganese induced Parkinsonism and the Caribbean Food toxins Parkinson plus syndromes. Read More

View Article and Full-Text PDF
December 2019

Genome-wide survey of copy number variants finds MAPT duplications in progressive supranuclear palsy.

Mov Disord 2019 07 6;34(7):1049-1059. Epub 2019 May 6.

Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.

Background: Progressive supranuclear palsy is a neurodegenerative tauopathy manifesting clinically as a progressive akinetic-rigid syndrome. In this study, we sought to identify genetic variants influencing PSP susceptibility through a genome-wide association analysis of a cohort of well-characterized patients who had participated in the Neuroprotection and Natural History in Parkinson Plus Syndromes and Blood Brain Barrier in Parkinson Plus Syndromes studies.

Methods: We genotyped single-nucleotide polymorphisms in 283 PSP cases from the United Kingdom, Germany, and France and compared these with genotypes from 4472 controls. Read More

View Article and Full-Text PDF

A Comparison of Pain between Parkinson's Disease and Multiple System Atrophy: A Clinical Cross-Sectional Survey.

Pain Res Manag 2019 22;2019:3150306. Epub 2019 Jan 22.

Department of Neurology, Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui 230000, China.

Background: Pain is frequent in Parkinson's disease (PD) and Parkinson-plus syndrome. This study aimed to assess the prevalence, characteristics, therapy (especially the effect of dopaminergic therapy), and associated symptoms of pain in Parkinson's disease and multiple system atrophy (MSA) patients.

Methods: Seventy-one PD patients, sixty-five MSA patients, and forty age-matched healthy controls were enrolled and evaluated by using the German pain questionnaire and visual analogue scale (VAS). Read More

View Article and Full-Text PDF

Self-reported urinary impairment identifies 'fast progressors' in terms of neuronal loss in multiple system atrophy.

Auton Neurosci 2019 03 14;217:1-6. Epub 2018 Dec 14.

Facultad de Medicina, Universidad de Chile, Santos Dummont 999, Santiago, Chile.

Introduction: MSA is an adult-onset, sporadic, progressive parkinsonian syndrome characterised by the presence of akinesia, cerebellar dysfunction, autonomic failure and pyramidal signs. Annualized-whole-brain atrophy rate (a-WBAR) is an informative way to quantify disease progression. In this longitudinal work we investigate the correlations of a-WBAR with clinical scales for motor impairment, autonomic disability and cognitive decline in MSA and explore how atrophy progresses within the brain. Read More

View Article and Full-Text PDF

Early perfusion and dopamine transporter imaging using F-FP-CIT PET/CT in patients with parkinsonism.

Am J Nucl Med Mol Imaging 2018 20;8(6):360-372. Epub 2018 Dec 20.

Department of Nuclear Medicine, Kyungpook National University Hospital Daegu, Republic of Korea.

Combined use of F-N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl)nortropane (FP-CIT) for dopamine transporter imaging and F-fludeoxyglucose (FDG) for glucose metabolism shows good diagnostic performance for differential diagnosis of Parkinson disease (PD) and Parkinson plus syndrome (multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, and dementia with Lewy bodies). A recent study showed that F-FP-CIT positron emission tomography (PET) with early perfusion imaging is useful for the differential diagnosis of PD and Parkinson plus syndrome with lower radiation exposure, time, and cost. In this review, we summarize the advantages of using F-FP-CIT PET for perfusion and dopamine transporter imaging, as well as clinical features useful for the differential diagnosis of PD and Parkinson plus syndrome. Read More

View Article and Full-Text PDF
December 2018

Glucose metabolic brain patterns to discriminate amyotrophic lateral sclerosis from Parkinson plus syndromes.

EJNMMI Res 2018 Dec 13;8(1):110. Epub 2018 Dec 13.

Department of Nuclear Medicine and Molecular Imaging, Division of Nuclear Medicine, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.

Background: F-FDG brain PET measures metabolic changes in neurodegenerative disorders and may discriminate between different diseases even at an early stage. The objective of this study was to classify patients with amyotrophic lateral sclerosis (ALS) and Parkinson plus syndromes (PP). To this end, different approaches were evaluated using generalized linear models and corresponding glucose metabolic brain patterns. Read More

View Article and Full-Text PDF
December 2018

Progress in the treatment of Parkinson-Plus syndromes.

Parkinsonism Relat Disord 2019 02 3;59:101-110. Epub 2018 Oct 3.

UC San Diego Department of Neurosciences, Parkinson and Other Movement Disorder Center, La Jolla, CA, USA. Electronic address:

Progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB) are the four major proteinopathic neurodegenerative disorders. Currently, there are no disease modifying therapies for these disorders. However, better understanding of the etiopathogenic mechanisms of these disorders has allowed the development of novel therapeutic approaches. Read More

View Article and Full-Text PDF
February 2019

What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective.

Parkinsonism Relat Disord 2019 02 30;59:93-100. Epub 2018 Aug 30.

Univ Lyon, Institut des Sciences Cognitives Marc Jeannerod, CNRS, UMR 5229, F-69675, Bron, France; Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Centre Expert Parkinson, Lyon, France; Univ Lyon, Faculté de Médecine et de Maïeutique Lyon Sud Charles Mérieux, F-69921, Oullins, France.

The diagnosis of a parkinsonian syndrome based on clinical criteria remains sometimes difficult, especially at disease onset. Brain or heart molecular imaging techniques (SPECT or PET) can provide a major help to improve and speed up diagnosis, influencing treatment strategies. Presynaptic dopaminergic imaging using either [F]-Dopa PET or I -2β-Carbomethoxy-3β-(4-Iodophenyl)- N-(3-Fluoropropyl) Nortropane ([I]-Ioflupane)SPECT demonstrates or rules out the presence of a dopaminergic degenerative process. Read More

View Article and Full-Text PDF
February 2019

Jean-Martin Charcot and Parkinson's disease: Teaching and teaching materials.

O Walusinski

Rev Neurol (Paris) 2018 Sep - Oct;174(7-8):491-505. Epub 2018 Apr 10.

Cabinet Privé, 20 rue de Chartres, 28160 Brou, France. Electronic address:

James Parkinson's 1817 seminal article was not well known in France until 1861, when Jean-Martin Charcot and his friend, Alfred Vulpian, published a detailed description in French of paralysis agitans. Their article provided clinical information to help French physicians make an accurate diagnosis by considering gait, shaking and rigidity as well as masked facies. As Charcot always had a strong desire to teach, this article describes his lessons on Parkinson's disease from 1868 to 1888, and also examines the teaching approach he used to pass on his latest findings to his students and colleagues. Read More

View Article and Full-Text PDF
December 2018